Motac offers a wide range of highly-specialised in vivo and ex vivo services to support the preclinical development of new treatments for neurodegenerative disorders, including Parkinson’s disease, other movement disorders and disorders of cognition.
State-of-the-art model systems, with excellent translational validity, are routinely available to demonstrate the efficacy of novel therapeutic approaches. These include acute and progressive models of neurodegeneration, Parkinson’s disease and drug-induced dyskinesias and cognitive performance.
Because of our extensive experience in these fields, we are able to offer expert advice on study design as well as performing studies to a high quality, according to standard operating procedures (SOPs) and to agreed timelines.
For further information on the models available, to discuss your requirements or to request a quotation, please contact us.